Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience

dc.authoridÇetinkaya, Duygu Uçkan/0000-0003-3593-6493
dc.authoridKüpeli, Serhan/0000-0001-7271-1803
dc.authoridCakmakli, Hasan Fatih/0000-0003-0152-1564
dc.authoridkaragun, barbaros sahin/0000-0002-7678-5524
dc.authoriduygun, vedat/0000-0003-3257-7798
dc.authoridAkcay, Arzu/0000-0001-8343-1153
dc.authoridkartal, ibrahim/0000-0002-2772-9956
dc.authorwosidÇetinkaya, Duygu Uçkan/X-2067-2019
dc.authorwosidKüpeli, Serhan/J-1588-2014
dc.authorwosidOk Bozkaya, Ikbal/P-4121-2015
dc.authorwosidCakmakli, Hasan Fatih/X-9341-2018
dc.authorwosidAtay, Didem/A-8647-2019
dc.authorwosidkaragun, barbaros sahin/AAB-8587-2019
dc.authorwosiduygun, vedat/AGH-4534-2022
dc.contributor.authorYesilipek, M. Akif
dc.contributor.authorUygun, Vedat
dc.contributor.authorKupesiz, Alphan
dc.contributor.authorKarasu, Gulsun
dc.contributor.authorOzturk, Gulyuz
dc.contributor.authorErtem, Mehmet
dc.contributor.authorSasmaz, Ilgen
dc.date.accessioned2024-08-04T20:51:44Z
dc.date.available2024-08-04T20:51:44Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractWe report the national data on the outcomes of hematopoietic stem cell transplantation (HSCT) for thalassemia major (TM) patients in Turkey on behalf of the Turkish Pediatric Stem Cell Transplantation Group. We retrospectively enrolled 1469 patients with TM who underwent their first HSCT between 1988 and 2020 in 25 pediatric centers in Turkey. The median follow-up duration and transplant ages were 62 months and 7 years, respectively; 113 patients had chronic graft versus host disease (cGVHD) and the cGVHD rate was 8.3% in surviving patients. Upon the last visit, 30 patients still had cGvHD (2.2%). The 5-year overall survival (OS), thalassemia-free survival (TFS) and thalassemia-GVHD-free survival (TGFS) rates were 92.3%, 82.1%, and 80.8%, respectively. cGVHD incidence was significantly lower in the mixed chimerism (MC) group compared to the complete chimerism (CC) group (p < 0.001). In survival analysis, OS, TFS, and TGFS rates were significantly higher for transplants after 2010. TFS and TGFS rates were better for patients under 7 years and at centers that had performed over 100 thalassemia transplants. Transplants from matched unrelated donors had significantly higher TFS rates. We recommend HSCT before 7 years old in thalassemia patients who have a matched donor for improved outcomes.en_US
dc.description.sponsorshipTurkish Society of Pediatric Hematologyen_US
dc.description.sponsorshipWe would like to thank Vedat Uygun for contributing to the statistics of the study. This study was supported by the Turkish Society of Pediatric Hematology.en_US
dc.identifier.doi10.1038/s41409-022-01613-w
dc.identifier.endpage767en_US
dc.identifier.issn0268-3369
dc.identifier.issn1476-5365
dc.identifier.issue5en_US
dc.identifier.pmid35210564en_US
dc.identifier.scopus2-s2.0-85125139401en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage760en_US
dc.identifier.urihttps://doi.org/10.1038/s41409-022-01613-w
dc.identifier.urihttps://hdl.handle.net/11616/100499
dc.identifier.volume57en_US
dc.identifier.wosWOS:000761872800003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone-Marrow-Transplantationen_US
dc.subjectCord Blood Transplantationen_US
dc.subjectLong-Termen_US
dc.subjectChildrenen_US
dc.subjectDiseaseen_US
dc.subjectDonoren_US
dc.titleThalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experienceen_US
dc.typeArticleen_US

Dosyalar